PharmaEngine (智擎) started 2026 with a regulatory milestone, announcing that its sublicense partner, Servier, has had its supplemental New Drug Application (sNDA) for ONIVYDE® as a first-line (1L) combination therapy for metastatic pancreatic ductal adenocarcinoma (PDAC) accepted by Japan's PMDA.

Strategic & Financial Implications:

• Milestone Revenue: PharmaEngine will recognize US$1.5 million in sublicense revenue following formal acceptance by the PMDA.
• Market Expansion: While ONIVYDE® is already established in second-line (2L) treatment, the move to 1L significantly increases utilization. On average, a 1L treatment cycle requires 32 vials compared to 12 vials for 2L, potentially doubling or tripling per-patient revenue.
• 2026 Outlook: Analysts expect PharmaEngine to return to double-digit growth in 2026 as 1L penetration increases in Europe, Taiwan, and eventually Japan. Projected EPS is estimated at NT$3.0 – 3.5.
• R&D Pipeline: The company is also advancing PEP07 (targeting MCL/AML, Phase I) and PEP08 (targeting MTAP-deficient tumors, specifically Glioblastoma), both of which represent significant out-licensing potential.

Resource: 智擎ONIVYDE一線胰臟癌日本申請獲受理150萬美元入袋，營運重回成長